Sana Biotechnology, Inc.

NasdaqGS:SANA 주식 리포트

시가총액: US$1.1b

Sana Biotechnology 경영진

경영진 기준 점검 4/4

Sana Biotechnology CEO는 Steve Harr, Sep2018 에 임명되었습니다 의 임기는 7.92 년입니다. 총 연간 보상은 $2.90M, 24% 급여 및 76% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $33.90M 가치에 해당하는 회사 주식의 2.99% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2 년과 7.8 년입니다.

핵심 정보

Steve Harr

최고경영자

US$2.9m

총 보수

CEO 급여 비율23.98%
CEO 재임 기간7.9yrs
CEO 지분 보유율3.0%
경영진 평균 재임 기간2yrs
이사회 평균 재임 기간7.8yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Jul 22

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Summary Sana Biotechnology is rated Sell due to excessive risk and overvaluation relative to its early-stage pipeline. Both lead assets, SC291 and SC451, are years from market and face low historical success rates, with SC291 only in Phase 1. The entire pipeline depends on the unproven Hypoimmune (HIP) platform; failure in early trials could invalidate the company. With $128.9M in cash and high burn, heavy dilution is likely for SANA, making the current $3.14 share price unjustified versus a $0.53 risk-adjusted fair value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Summary SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient. SANA also has ongoing Phase 1 trials for SC291 and SC262, with topline data expected in 2025. However, SANA does have high cash burn and dilution risks, which is why I just rate it a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Summary Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense. I rate SANA stock as a “Buy,” but advise caution as the stock may correct downward before long-term growth, given the early stage of clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Dec 04

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. The global Lupus drugs market is expected to reach $4.2 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Nov 19

Sana Biotechnology: The Story Becomes Murkier

Summary Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future. An updated analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
분석 기사 • Nov 01

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jul 14

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Summary Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively. Read the full article on Seeking Alpha
분석 기사 • Jul 12

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 17

Sana Biotechnology: Now In Overbought Territory

Summary Sana Biotechnology's shares have risen some 60% since a secondary offering in February, driven by positive early clinical and research results. The company is focused on developing engineered cells to treat diseases, using a hypoimmune technology platform to create cells that evade immune detection. Sana has three clinical programs in Phase 1 trials, with promising results seen in the treatment of B-cell cancer and type I diabetes. A full analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Summary Sana Biotechnology's novel T1D treatment, not requiring immunosuppression, shows encouraging results in a non-human primate study. Sana displays improved Q3 financials with a current ratio of 4.03, but faces high cash burn and potential funding needs. Investment Stance: Shift from "Sell" to "Hold" based on Sana's financial management and R&D progress, with a watchful eye for further clinical and financial developments. Read the full article on Seeking Alpha
분석 기사 • Dec 30

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
분석 기사 • Sep 14

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • May 26

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Dec 19

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Sep 03

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jun 27

Sana Biotechnology A Buy For Potential Cancer Therapies

Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology. Clinical trials could begin in 2023, following INDs in 2022.
분석 기사 • May 16

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Feb 12

Sana Biotechnology: Exciting Preclinical Science

Sana was formed by founders of Juno. It has very exciting science and encouraging preclinical data. However, risks abound.

CEO 보수 분석

Steve Harr의 보수는 Sana Biotechnology의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Jun 30 2026n/an/a

-US$212m

Mar 31 2026n/an/a

-US$242m

Dec 31 2025US$3mUS$696k

-US$244m

Sep 30 2025n/an/a

-US$234m

Jun 30 2025n/an/a

-US$252m

Mar 31 2025n/an/a

-US$209m

Dec 31 2024US$9mUS$681k

-US$267m

Sep 30 2024n/an/a

-US$306m

Jun 30 2024n/an/a

-US$245m

Mar 31 2024n/an/a

-US$309m

Dec 31 2023US$3mUS$659k

-US$283m

Sep 30 2023n/an/a

-US$276m

Jun 30 2023n/an/a

-US$362m

Mar 31 2023n/an/a

-US$320m

Dec 31 2022US$4mUS$645k

-US$269m

Sep 30 2022n/an/a

-US$300m

Jun 30 2022n/an/a

-US$298m

Mar 31 2022n/an/a

-US$207m

Dec 31 2021US$1mUS$611k

-US$356m

Sep 30 2021n/an/a

-US$358m

Jun 30 2021n/an/a

-US$327m

Mar 31 2021n/an/a

-US$433m

Dec 31 2020US$7mUS$535k

-US$285m

보상 대 시장: Steve의 총 보수(USD2.90M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.51M) 수준입니다.

보상과 수익: Steve의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Steve Harr (56 yo)

7.9yrs
재임 기간
US$2,903,010
보수

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

리더십 팀

이름직위재임 기간보수지분
Steven Harr
President7.9yrsUS$2.90m2.99%
$ 33.9m
Brian Piper
Executive VP & CFOless than a year데이터 없음데이터 없음
Susan Wyrick
Treasurer1.8yrs데이터 없음0.065%
$ 742.2k
Snehal Patel
Senior VP & Chief Technical Officer2.6yrs데이터 없음데이터 없음
Dhavalkumar Patel
Executive VP & Chief Scientific Officer2yrs데이터 없음0.033%
$ 376.5k
Aaron Grossman
Executive VPless than a year데이터 없음데이터 없음
Debra Wisdom
VP & Head of Peopleno data데이터 없음데이터 없음
Gary Meininger
Chief Medical Officer3.3yrs데이터 없음데이터 없음
Yuko Soneoka
Head of Intellectual Property2yrs데이터 없음데이터 없음
John Gerecitano
Head of Oncology Research & Development2yrs데이터 없음데이터 없음
2.0yrs
평균 재임 기간
54yo
평균 나이

경험이 풍부한 관리: SANA의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2 년).

이사회 구성원

이름직위재임 기간보수지분
Steven Harr
President7.8yrsUS$2.90m2.99%
$ 33.9m
Robert Taylor Nelsen
Independent Director7.8yrsUS$162.79k0.0046%
$ 52.4k
Yuhmin Yang
Independent Director7.8yrsUS$167.79k0.050%
$ 564.7k
Michelle Seitz
Independent Director5.8yrsUS$182.79k0%
$ 0
Richard Mulligan
Vice Chairman7.8yrsUS$162.79k0.90%
$ 10.2m
Hans Edgar Bishop
Independent Chairman of the Board7.8yrsUS$220.51k1.95%
$ 22.1m
Joshua Bilenker
Independent Director5.7yrsUS$169.52k0.0067%
$ 75.7k
Alise Reicin
Independent Director5.7yrsUS$170.29k0%
$ 0
Robert Rosiello
Independent Director1.2yrsUS$230.70k0%
$ 0
7.8yrs
평균 재임 기간
64yo
평균 나이

경험이 풍부한 이사회: SANA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.8 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/12 15:10
종가2026/08/12 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sana Biotechnology, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Alec StranahanBofA Global Research
Samantha Lynn SemenkowCitigroup Inc
Reni BenjaminCitizens JMP Securities, LLC